Metalyse (Tenecteplase)

Tenecteplase is a recombinant tissue‑type plasminogen activator that binds to fibrin within a clot and converts plasminogen to plasmin. Plasmin then degrades fibrin strands, breaking down the clot and allowing normal blood flow to resume.

The dose of Metalyse is determined by the prescribing clinician based on the patient’s weight, clinical condition, and local treatment guidelines. It is given as a single intravenous bolus under medical supervision.

Safety data for tenecteplase in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Metalyse, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Both Metalyse (tenecteplase) and alteplase are fibrinolytic agents, but tenecteplase has higher fibrin specificity and a longer plasma half‑life, allowing a single bolus administration. Alteplase typically requires an infusion over several minutes, whereas Metalyse simplifies dosing and may reduce administration time.

Metalyse should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Before use, inspect the solution for particulate matter or discoloration and follow aseptic techniques for intravenous administration.

Metalyse is given as a single intravenous bolus injection. The preparation is a sterile solution for injection, and the administration must be performed by qualified healthcare personnel in a setting equipped for cardiac emergency care and monitoring.

The most serious risks include intracranial hemorrhage, severe systemic bleeding, allergic reactions such as anaphylaxis, and myocardial rupture. Prompt recognition of bleeding signs and immediate medical intervention are essential during and after infusion.

Metalyse is contraindicated in patients with active internal bleeding, recent intracranial surgery or hemorrhage, known hypersensitivity to tenecteplase, or those who have received another fibrinolytic agent within the previous 24 hours. Clinicians must assess each patient’s risk profile before prescribing.